C. difficile 위험도


Community-acquired pneumoniaAcute exacerbation of chronic bronchitis (AECB)Acute bacterial sinusitisUncomplicated SSTIComplicated SSTIComplicated intraabdominal infection400 mg PO q24h x7-14d400 mg PO/IV q24h x5d400 mg PO/IV q24h x10d400 mg PO/IV q24h x7d400 mg PO/IV q24h x7-21d400 mg PO/IV q24h x5-14dMay switch from IV to oral administration without dose adjustmentNo renal dose adjustment

Safety and efficacy in pediatric patients <18y of age have not been established

No dose adjustment

General Information

  • Pneumonia including CAP, HAP, aspiration

  • Some intra-abdominal infections

  • CNS infections

Black Box Warning:

  • Discontinue moxifloxacin and avoid use of fluoroquinolones in patients with these serious adverse reactions.

  • Reserve use of moxifloxacin for patients with no alternative treatment options for acute bacterial sinusitis or acute bacterial exacerbation of chronic bronchitis.

  • Avoid in patients with known history of myasthenia gravis.

Monitor QTc in patients with increased risk.

Monitor creatinine BUN in patients with impaired renal function.

Monitor serum magnesium levels, hematopoietic, renal and hepatic functions.

Perform serologic syphillis testing upon diagnosis of gonorrhea with follow-up testing 3 months after initiation.

Perform ophthalmologic evaluations in patients reporting visual disturbances.

Clostirdioides difficile overgrowth patients with diarrhea.

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

  • QTc prolongation - increased risk with other agents that prolong QTc

  • Divalent cations including Ca, Mg - decreased absorption

  • Warfarin - increased INR

  • Rifampin - decrease moxifloxacin levels

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 10-14 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.